hydrochlorothiazide and drospirenone

hydrochlorothiazide has been researched along with drospirenone in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andricopulo, AD; Moda, TL; Montanari, CA	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Alonso, A; Blode, H; Hanes, V; Karara, AH; Ni, P; Poola, N; Preston, RA; Silang, R	1

Trials

1 trial(s) available for hydrochlorothiazide and drospirenone

Article	Year
Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. Journal of clinical pharmacology, 2007, Volume: 47, Issue:10 Topics: Aged; Aldosterone; Androstenes; Antihypertensive Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Postmenopause; Potassium	2007

Article

Year

Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.

Journal of clinical pharmacology, 2007, Volume: 47, Issue:10

Topics: Aged; Aldosterone; Androstenes; Antihypertensive Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Postmenopause; Potassium

2007

Other Studies

2 other study(ies) available for hydrochlorothiazide and drospirenone

Article	Year
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

Hologram QSAR model for the prediction of human oral bioavailability.

Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013